{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:46:05Z","timestamp":1762253165979,"version":"3.41.2"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p> The influenza virus causes significant human morbidity and mortality annually and poses a pandemic threat. In addition, the virus frequently mutates, contributing to thousands of identified strains. Current influenza vaccine solutions are strain specific, target existing strains, and achieve only approximately 40% vaccine effectiveness (VE). The need for broadly protective Universal Influenza Vaccines (UIVs) is clear. UIV research and development efforts focus on widely conserved (i.e. not strain specific) influenza epitopes. The most clinically advanced UIV candidate, the Multimeric-001 (M-001), is currently undergoing a pivotal, clinical efficacy, phase III trial. Completed clinical trials indicate M-001 is safe, well tolerated, and immunogenic to a broad range of influenza strains. Additional candidates are also under development, supported by public and private funding. Research results suggest that it is only a matter of time until a broadly protective influenza vaccine is approved for licensure. <\/jats:p>","DOI":"10.1177\/2515135519885547","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T12:21:47Z","timestamp":1573129307000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Is a universal influenza vaccine feasible?"],"prefix":"10.1177","volume":"7","author":[{"given":"Joshua E.","family":"Phillipson","sequence":"first","affiliation":[{"name":"BiondVax Pharmaceuticals Ltd., Jerusalam BioPark building, Floor 2, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Babecoff","sequence":"additional","affiliation":[{"name":"BiondVax Pharmaceuticals Ltd., Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-8436","authenticated-orcid":false,"given":"Tamar","family":"Ben-Yedidia","sequence":"additional","affiliation":[{"name":"BiondVax Pharmaceuticals Ltd., Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"bibr1-2515135519885547","unstructured":"National Institutes of Health. Influenza, https:\/\/report.nih.gov\/nIHfactsheets\/ViewFactSheet.aspx?csid=133 ."},{"key":"bibr2-2515135519885547","unstructured":"World Health Organization. Influenza (Seasonal), http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/ ."},{"key":"bibr3-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2"},{"key":"bibr4-2515135519885547","unstructured":"Center for Disease Control and Prevention. Deaths and mortality, http:\/\/www.cdc.gov\/nchs\/fastats\/deaths.htm ."},{"key":"bibr5-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.046"},{"key":"bibr6-2515135519885547","unstructured":"Center for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies, https:\/\/www.cdc.gov\/flu\/professionals\/vaccination\/effectiveness-studies.htm"},{"key":"bibr7-2515135519885547","unstructured":"World Health Organization. http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/2a_Graham_pdvac_sept14.pdf Slide 3 (accessed January 2017)."},{"key":"bibr8-2515135519885547","unstructured":"Scientific American. How are seasonal flu vaccines made? https:\/\/www.scientificamerican.com\/article\/how-are-seasonal-flu-vaccines-made\/ (accessed January 2017)."},{"key":"bibr9-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1714916"},{"key":"bibr10-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(06)80037-3"},{"key":"bibr11-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.07.005"},{"key":"bibr12-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1240041"},{"key":"bibr13-2515135519885547","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001395"},{"key":"bibr14-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9632-5"},{"key":"bibr15-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.031"},{"key":"bibr16-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00088-I"},{"key":"bibr17-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(98)00045-1"},{"key":"bibr18-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.7.1043"},{"key":"bibr19-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006339"},{"key":"bibr20-2515135519885547","unstructured":"Guideline on Influenza Vaccines. Non-clinical and clinical module EMA\/CHMP\/VWP\/457259\/2014"},{"key":"bibr21-2515135519885547","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010033"},{"key":"bibr22-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.089"},{"key":"bibr23-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0098-4"},{"key":"bibr24-2515135519885547","unstructured":"National Institutes of Health. NIH begins first-in-human trial of a universal influenza vaccine candidate, https:\/\/www.nih.gov\/news-events\/news-releases\/nih-begins-first-human-trial-universal-influenza-vaccine-candidate."},{"key":"bibr25-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-017-0918-y"},{"key":"bibr26-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"bibr27-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.074"},{"key":"bibr28-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161193"},{"key":"bibr29-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.063"},{"key":"bibr30-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1922"},{"key":"bibr31-2515135519885547","unstructured":"Markey ED. Senator Markey and Rep. DeLauro reintroduce legislation to more than double investment in universal flu vaccine, https:\/\/www.markey.senate.gov\/news\/press-releases\/senator-markey-and-rep-delauro-reintroduce-legislation-to-more-than-double-investment-in-universal-flu-vaccine (2019)."},{"key":"bibr32-2515135519885547","unstructured":"https:\/\/www.markey.senate.gov\/imo\/media\/doc\/Flu%20Vaccine%20Act.pdf"},{"key":"bibr33-2515135519885547","unstructured":"https:\/\/www.influenzer.org\/app\/uploads\/2019\/07\/sabin-aspen-report-digital.pdf"},{"key":"bibr34-2515135519885547","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy103"},{"key":"bibr35-2515135519885547","unstructured":"National Institutes of Health. NIAID-sponsored trial of a universal influenza vaccine begins, https:\/\/www.niaid.nih.gov\/news-events\/niaid-sponsored-trial-universal-influenza-vaccine-begins. (accessed 4 May 2018)."}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135519885547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2515135519885547","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135519885547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T20:36:37Z","timestamp":1740774997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2515135519885547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":35,"alternative-id":["10.1177\/2515135519885547"],"URL":"https:\/\/doi.org\/10.1177\/2515135519885547","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"type":"print","value":"2515-1355"},{"type":"electronic","value":"2515-1363"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"2515135519885547"}}